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Daniel Schnorbus 
Introduces Himself 
As TAP's New 
Client Services Coordinator 
I would like to introduce myself. My name is Daniel 
Schnorbus and I am the new Client Services Coordinator of The 
AIDS Project. I have replaced Rodney Mondor. We all wish him 
the best ofluck in his work at the University of Southern Maine. 
I have recently relocated to Portland from Indiana where I 
graduated from Franklin College with an undergraduate degree 
in psychology. I have had the privilege of working with a variety 
of non-profits including Habitat for Humanity and The Sisters of 
St. Francis at Michaela Farm. It is my great hope that I can 
contribute to the sense of community and camaraderie at The 
AIDS Project by utilizing the skills I learned at those organiza-
tions. I look forward to acting as your Client Service Coordinator. 
From the buzz around the office I have learned that we have a 
dedicated pool of reliable volunteers. On behalf of The AIDS 
Project and those we assist, I want to thank them for their diligent 
work. Their efforts are greatly appreciated and needed. With the 
assistance of volunteers we are able to do our jobs much more 
efficiently. We cannot thank them enough for their contributions. 
In this position it is a personal goal to make the volunteer 
experience at The AIDS Project as rewarding and simple as 
possible. Volunteer work is a mutual give and take when the 
process enriches both the helper and the one that is helped. It can 
be inspiring, emotional, and sometimes even humorous for all 
parties involved. In my adventures with helping out I have 
learned that I always get much more from the experience then I 
give. 
If you would like to join our existing group of volunteers to 
offer some of your time, please contact us. We would appreciate 
what you have to offer and I am confident that it would be a 
rewarding experience for you. We have a variety of tasks that 
need to be accomplished. One is certain to be tailored to your 
personal strengths, preferences, and schedule. 
Thanks again for all of the work that volunteers have done 
and, of course, we welcome new volunteers. We look forward to 
hearing from you. 
PRO.JECT 
TH a IDS 
PRO.JECT 
s 
PRO.JECT 
TH a 
THAIDS 
PRO.JECT 
PRO.JECT 
PRO.JECT 
in your new job! To contact Daniel at TAP, call 77 4-68 77. ··~ 
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Editor's note: A big welcome to you, Daniel, and all the best t 
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What is it about this time of year that seems so 
peaceful on the one hand and so stressful on the other 
hand? Perhaps the stressful part is due to our desire to 
have a perfect holiday season. A few years back, it 
dawned on me that I wasn't really enjoying the holi-
days. The expectations that my family and I had were a 
little out of line when it came to the reality of the 
season. We were working so hard to make Christmas 
such a perfect time that we couldn't possibly have had 
a happy day. We would fret and worry so over all the 
little details that we were beginning to miss the big 
picture. Which is that the holidays are about getting 
together and enjoying each other's company. So if the 
house isn't spotless and the food isn't to everyone's 
exact specifications, it doesn't matter as long as we 
remember it's all about being together, sharing 
memories and sharing some laughs. I am happy to 
report, we've gotten much better at enjoying the 
holidays. I truly hope you, too, enjoy the holiday season. 
With the new year just around the corner, I'd like 
to stop for a second and just say thanks to all who have 
made this past year interesting, to say the least. Thanks 
to my family and friends for your aide and comfort. I am 
also particularly thankful to all the folks at The AIDS 
Project. You are a dedicated group of individuals who do 
great work together. The work never ceases, and you 
rise to the challenge every day. 
There is one person in my life that I would be 
remiss if I didn't single her out. That's my Mom. Suffice 
it to say, Mom has made my life very comfortable. She 
still can make me laugh at the silliest little things. And 
my three brothers and I know that she loves us very 
much. And we love her back. 
The year has not always run smoothly. News of 
better treatments and more treatment options for 
people with HIV and AIDS is good, but that is leavened 
with the knowledge that not all have benefitted from the 
good news. Some people who are living longer are not 
necessarily living better. People are still getting sick and 
dying from AIDS. And, horrifically, the number of new 
HIV infections is not dropping at all. There is no end in 
sight. 
Recently a person I first met at an HIV support 
group ten and a half years ago (at The AIDS Project back 
when it had office space on Deering Street) died. The 
obituary made no mention that he had AIDS. Was it 
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shame or merely privacy that made the family exclude 
this highly significant fact? I don't know. It reminded 
me, however, that there are still many people with HIV 
and AIDS who are afraid to be open about their status. 
Some worry about being rejected by family and/or 
friends. Some worry about the reaction of their co-
workers or supervisors. Some worry about their 
personal safety if they make their HIV status known 
publicly. We may have come a long way with treatment 
for this disease, but there is still a lot of fear out there. 
This fear can translate into depression, loss of self· 
esteem, not seeking medical treatment, and being 
isolated from the world. There is still a lot of work to be 
done in helping people come to terms with their lives. 
Lives significantly affected by HIV and AIDS. 
One of the folks who has made AIDS better 
known in Maine, who helped to drag it out of the closet, 
is Frannie Peabody. Well into her 90's, Frannie contin-
ues to get out in public and beat the bushes for The 
AIDS Project and Peabody House. She is a treasure. 
Thanks to Frannie for all her good work and personal 
attention to people with HIV and AIDS. 
Last fall, I gave Frannie a ride to and from a board 
meeting for The AIDS Project. After I dropped her off at 
her home (politely walking her into her home and 
making sure she was all set, as I was brought up to do 
these things), I backed out of her driveway and drove 
past her front door. Standing inside the door and looking 
through the window, Frannie waved goodbye as I 
headed home. It reminded me very much of the many 
times I visited my grandmother and upon driving away, 
she would wave to me from her window. My grand-
mother, Rose, died nearly six years ago. It was always 
so sweet when my grandmother waved goodbye, and 
so comforting. Frannie is a comfort to so many people 
and in ways even she might not know. 
H. L. Mencken once wrote that his job as a 
journalist was to "comfort the afflicted and afflict the 
comfortable." HIV and AIDS is often uncomfortable, for 
those infected and for those who live in fear of it. For 
those who are beginning to get a little too comfortable, 
and a little too unconcerned, about HIV, I say don't rest 
easy. The epidemic is far from over. For those who 
know full well what it is like to be HIV-positive or to be 
diagnosed with AIDS, I hope that some comfort comes 
to you and the ones you love atthis special time of year. 
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Board of Directors: 
Joel C. Martin, Esq., President 
Michael Martin, Vice President 
Anne M. Romano, CPA, Treasurer 
JoAnne Peterson, Secretary 
Editor's Note: As 1998 draws to a close, it is a good time 
to reflect on the fact that it takes a lot of dedicated people to keep 
The AIDS Project working to fulfill its mission of providing 
support services to people infected and affected with HIV and 
AIDS and to provide prevention education to as many people as 
possible in the four counties we currently serve in southern 
Maine. Also, we give thanks to the many volunteers who over the 
years have helped make the lives of people with HIV and AIDS 
more bearable and who have made the work of The AIDS Project 
run more smoothly. 
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Lawrence Bliss The AIDS Project 
Michael Burnham 615 Congress Street - 6th Floor 
Jerrold C. Edelberg, Ph.D. (or 142 High Street) 
Dino Giamatti P.O. Box 5305 
Judi Mansing Portland, Maine 04101 
Karla B. McGowan Phone: 774-6877 Fax: 879-0761 
Frances W. Peabody E-mail: tap@aidsproject.org 
John Wade Website: www.aidsproject.org 
Christopher Warner AIDS Hotline: 775-1267 
Verne Weisberg, M.D. or 1-800-851-2437 
Roberta M. Wright 
Oxford/ Androscoggin Cty. Office 
Advisory Board: One Auburn Center/Box 14L 
Auburn, ME 04210 
Bettsanne Holmes, Chair Phone: 783-4301 Fax: 795-4084 
Josiah K. Adams York County Office 
Peter C Barnard Lafayette Center - 4th Floor 
Joan B. Burns Kennebunk, ME 04043 
Peter L. Chandler, CPA Phone: 985-8199 
Madeleine G. Corson Fax: 985-8646 *51 
Maria P. Damerel 
Josiah H. Drummond, Jr. Staff: 
Alice Gemmer 
Pamela W. Gleichman Doug Bailey, 
Sandra Goolden HAVEN I Housing Coordinator 
Celeste Gosselin Declan Buckley, 
Jonathan W. Karol, D.O. MSM Outreach Worker 
Leo J. LaPlante, CPA Diana Carrigan, 
Pamela Knowles Lawrason, Esq. Androscoggin and Oxford Counties 
George M. Lord Case Manager 
Mallory K. Marshall Janine Collins, 
Mary Jean Mork Cumberland County Case Manager 
Gwendolyn C. O'Guin, D.O. John Cronin, 
Patricia M. Pinto MSM Outreach Worker 
Lois Galgay Reckitt Caroline Curtis, 
Victoria A. Rochefort Case Management Intern 
Lynn E. Shaffer Sequoia Dance, 
Elizabeth 0 . Shorr Street Outreach Worker 
John H. Siegle, M.D. Douglas Eaton, 
Cynthia Sartwell, M.D. Program Coord. of HIV Prevention 
Seth Sprague Denise Ferrer, 
James F. Tomney York County Case Mngmt. Intern ; 
Virginia W. Truesdale 
Margaret Wiles 
Jean T. Wilkinson 
Margo Wintersteen 
Roger F. Woodman 
Frances R. Zilkha 
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Jill Frame, 
HAVEN Case Manager 
George W. Friou, 
Executive Director 
Demetra Giatas, 
Development Director 
John Green, 
HIV Case Manager 
John Holverson, 
Director of Policy & Program 
Gloria Leach, 
Community HIV Prev. Educator 
Annette Lemek, 
Case Management Intern 
Randy May, 
Director of Support Services 
Robert Moore, 
African-American Outreach Worker 
Rebecca Neel, 
Cumberland and York Counties 
Case Manager 
Susan Parr, 
Cumberland County Case Manager 
Getty Payson, 
York County Case Manager 
Steve Reevy, 
Manager I Finance & Administration 
Daniel Schnorbus, 
Client Services Coordinator 
Gerry Scoppettuolo, 
York County Field Outreach Worker 
David Aaron Swander, 
Education I Development Assistant 
Kelly Tardif, 
Admin. I Case Mngmt. Assistant 
Arthur Waller, 
Accounting Assistant 
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Susan Parr, one of TAP's case 
managers, will be starting an 
Expressive Therapy group for people 
living with HIV and AIDS. In this 
group, creativity will be expl~red ~ 1Jt Af'DS /)'2o. • 
through art, movement, music, * ~ 
storytelling, play, and writing. ~ :.,..l-
Absolutely no experience is 
needed! The group will provide time 
for self-discovery, reflection, and 
relaxation. Please call Susan if you 
are interested in the group or would 
like more information. Call Susan at 
TAP at 774-6877. 
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For those persons with HIV who attended this past 
summer's Reconstruction Forum, Randy Norcross of the 
Maine AIDS Alliance has passed along some of the 
comments from the last session where the participants 
expressed further needs around rebuilding their lives. 
The Forum explored the particular needs of those folks 
with HIV who are exploring a longer future than they had 
previously thought possible. 
Some of the comments and conclusions were: 
1) We need a group in order to explore dating issues. 
We don't know how to go about dating again. This group 
needs to include both HIV-positive and HIV-negative 
persons. We don't know what those who are HIV-
negative expect or fear. This group will need a profes-
sional facilitator. 
2) Each area in Maine needs a case manager who is 
specifically trained in rehabilitation issues. We mean the 
kinds of issues explored this summer in the 
Reconstruction sessions. This service would have to be 
designed for people who are living longer and take into 
consideration all of our unmet needs. 
3) We need a support group to look at "reasonable 
expectations" for us. We can't live up to the expecta-
tions of the media. 
4) We need a workshop in career counseling. This 
should be done in two sessions. The first group should 
include HIV-positive persons who make their 
career/work needs known. These must become 
concrete and put onto paper. The second group should 
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AIDS 
Update . 
Maine Cases of AIDS -832 
Maine Deaths from AIDS -443 
U.S. Cases of AIDS -641,068 
U.S. Deaths from AIDS -390,692 
Includes all cases since reporting began. 
Maine stats as of 9/98; U.S. stats as of 12/97. 
Maine AIDS Cases include only those who 
resided in Maine at the time of their diagnosis. 
By Mike Martin 
include an agency, like the Training Resource Center in 
Portland, to consult with us. 
5) We would like each AIDS Service Organization 
that publishes a newsletter to have a "Reconstruction 
Corner" to discuss the issues described in these unmet 
needs. 
6) We need a group or workshop to discuss the 
spiritualism that allows each of us to continue. We are 
not talking religion here, but there is a spiritual layer that 
each of us relies on. We need to be able to articulate that 
for ourselves and others. 
7) How do we reach the "silent"? How do we reach 
those HIV-positive persons who are not connected to the 
system by choice? How do we keep them appraised of 
what is available? 
8) We need an information packet with info provided 
on each of the topics covered by the Reconstruction's 
eight sessions. Every AIDS Service Organization needs 
to have such a packet, to be made available through their 
case management departments. 
Having talked to Randy Norcross about these 
results, he told me that the first area he felt needed to be 
addressed was the training of case managers through-
out the state of Maine around the needs of people with 
HIV who are trying to plan for the future, whether that 
means going back into the workforce or some other 
future endeavors. Randy is spearheading the follow-up 
to Reconstruction and he will keep us informed. 
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lndinavir (Crixivan®) 
Twice Daily Dosing Warning! 
Project Inform (11 /98) 
New information from a study of indinavir (Crixivan®) 
has shown that a twice daily dosing regimen (1,200 mg 
taken every 12 hours for a total daily dose of 2,400 mg) is 
not as effective as the standard three times daily schedule 
after 24 weeks. As a result, Merck, the manufacturer, 
stopped the part of the study that uses twice daily dosing 
and has notified the public of the new findings. These 
results are contrary to a previous, smaller 24-week study 
which suggested that twice daily dosing was at least 
equivalent to the standard dosing regimen (800 mg taken 
every 8 hours for a total daily dose of 2,400 mg), Based on 
these findings, the company is encouraging everyone 
using twice daily dosing to switch back to three times daily 
dosing. 
This Merck 069 study included people who had never 
previously taken a protease inhibitor and had never 
previously taken 3TC. The regimen included All, 3TC and 
indinavir, either given twice or three time daily. All 
participants received twice daily dosing of 3TC. 
After 24 weeks of study, 91% of those receiving three 
times daily dosing had HIV levels below the limit of 
detection ( < 400 copies HIV RNA), computed to 64% on 
twice daily dosing. One important lesson from this study is 
that after 16 weeks of observation, the twice daily dosing 
schedule appeared equivalent to the three times day 
regimen. By 6 months, however, the superiority of three 
times daily dosing became very apparent. 
Since this is a very preliminary look at the results, there 
are still unresolved questions. For instance, did people 
receiving the twice-daily indinavir regimen, who also 
received Arr twice daily (300 mg twice a day for a total 
daily dose of 600 mg), have more side effects because of 
the high peak drug levels of both drugs (the risk of side 
effects increases when drug levels are increased)? Other 
questions are raised as well. Would these results be 
different if people started out on d4T instead of Arr as it is 
generally better tolerated? Would someone who started on 
three times daily indinavir and went below the limit of 
detection do as well if they switched to twice daily 
indinavir compared to if they stayed on a three times a day 
regimen? Are people who simply cannot adhere to a three 
times daily dosing regimen better off continuing to struggle 
with that regimen (and possibly failing to adhere) or 
committing to a potentially less potent twice daily dosing 
with better adherence? In any case, it's important health 
care providers and people living with HIV are aware of the 
superiority of the three times daily dosing of indinavir, as 
many doctors and patients have already made the switch 
to twice daily dosing. 
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lndinavir, in combination with another protease inhibitor, 
is still being studied for twice daily dosing in other studies. 
One combines indinavir with ritonavir. Ritonavir is able to 
substantially increase indinavir levels in blood as well as 
slow the rate at which indinavir is passed out of the body. 
Preliminary, short-term studies appear to show that this 
regimen allows indinavir to work well with twice daily 
dosing, while the combination also seems to eliminate the 
need to avoid taking food with indinavir. 
However, it's important to recognize this is based on 
very early data. Studies are ongoing to determine the 
optimal doses of indinavir and ritonavir when used 
together. Another study combines indinavir with nelfinavir 
with both drugs being taken twice a day. Longer-term data 
will help confirm whether the drug is useful when used in 
these combinations in twice daily dosing regimens. 
Caution About Regimen Changes 
The lesson learned here is something that Project Ir.form 
has been cautioning about for some time with regard to 
simpler and easier regimens using current available 
therapies. When these drugs were approved, the reason 
they were dosed according to schedules in their label 
instructions (e.g. three times daily) is because studies 
demonstrated these schedules were necessary to 
maintain optimal blood levels of drugs. While people want, 
need and deserve simpler regimens, simply changing a 
regimen from three times to twice daily dosing is not the 
solution. The lesson here is that it takes larger, long-term 
studies to accurately determine how well a drug works in 
different dosing regimens. It can be potentially dangerous 
to make treatment decisions based on small exploratory 
studies. 
Leyoutand Design by 
In The Affirmative is a monthly 
newsletter published by The AIDS 
Project for people living with and 
affected by HIV/ AIDS. Letters. 
articles, or other submissions should 
be sent to: In The Affirmative, c/o 
The AIDS Project, P.O. Box 5305, 
Portland, ME 04101, or call (2071 
77 4-6877. Submissions can be 
printed anonymously as long as the 
person submitting the material 
includes his or her name and phone 
number for verification. 
News, information, and features 
are as up-to-date as possible prior to 
publication. Any medical information 
included in this newsletter is 
submitted for the reader's 
information only, to be used as the 
reader so chooses. 
IN THE AFFIRMATIVE 
Sources for some of the information 
in this newsletter include: 
The Daily AIDS News Summary 
from the CDC 
The New York Times Online 
The Portland Press Herald 
USA Today 
Contributors include: 
Karla McGowan 
Randy Norcross 
Susan Parr 
Daniel Schnorbus 
People Art © David Cedrone 
Kerry Tardif, Distribution 
Mike Martin, Editor 
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Treatment Flushes HIV From Blood 
USA Today (11/16/98) 
Three HIV-infected patients appear 
to have had virtually all of the virus 
cleared from their system following 
treatment with standard anti-HIV drugs 
and interleukin-2. The treatment was 
designed to flush HIV from latently 
infected cells in order expose it to the 
anti-HIV medications. Fourteen patients 
were treated in this manner; investiga-
tors, led by Tae-Wook Chun, could not 
grow live HIV from 330 million immune 
cells taken from three of the patients. 
However, Robert Siliciano of Johns 
Hopkins University cautioned that even 
with the large number of cells taken, the 
three patients could still harbor the 
virus. Anthony Fauci, director of the 
National Institute of Allergy and 
Infectious Diseases, also warned that it 
is still too early to speak of the treatment 
as a cure. He said thatthe patients will 
soon be taken off their drug regimen to 
determine if there are hidden areas of 
infection. "It's conceivable that we'll 
take these people off their drugs and the 
virus will come roaring back from a 
reservoir we didn't find," noted Fauci. 
The Trouble With Ritonavir 
POZ (11/98) 
Abbott Laboratories indefinitely 
halted in July production of the protease 
inhibitor ritonavir over concerns about · 
crystals in the drug's capsules. The 
crystals are not contaminated, but 
Abbott does not yet know what caused 
them or how they can be removed. 
Although the dafective drugs wera 
caught before distribution, pharmacies 
may soon run out of existing stocks. 
Until the problem is solved, ritonavir 
capsule users can switch to the liquid 
version, which is identical in composi-
tion and price to the capsules . 
Differences between the two forms 
includethefactthatthe liquid should not 
be refrigerated -- while the capsules 
should -- and that the liquid ritonavir has 
a high alcohol content, possibly raising 
concerns for recovering alcoholics or 
people with liver disease or hepatitis. 
Many people have also said that the 
liquid tastes unpleasant, a factor that 
could raise adherence issues for those 
who cannot stand to take it. 
Coping with Ritonavir (Liquid) 
Project Inform ( 11 /98) 
Unlike the liquid ritonavir formulation used 
in experimental studies, the current liquid 
formulation should NOT be refrigerated, but 
rather stored at room temperature (between 
68-77 degrees F or 20-25 degrees C). 
Additionally, before each use the bottle needs 
to be shaken well and used within 30 days of 
receiving it from the pharmacy. If it is stored in 
the refrigerator there is greater risk the 
crystalline structure will appear, and if stored 
in too warm an environment it might lose anti-
HIV activity. Should the crystalline structure 
appear it can be clearly seen through the bottle 
when held up to light. Vigorously shaking the 
bottle can dissolve the crystals and the drug 
will work normally. However, if the crystals do 
not dissolve, a new prescription needs to be 
obtained. 
Unpleasant Taste 
The liquid formulation has a very unpleasant 
taste. The drug can be combined with 
chocolate milk or nutritional supplements 
such as Advera or Ensure before each dose to 
mask the taste (but don't combine them more 
than an hour before taking the dose). Fatty 
and/or salty foods can also mask the taste. 
Taste tests show that the following can help 
with the taste: Nutella hazelnut spread on 
graham crackers; Riesen chocolate chew; 
oats and honey granola bar; and toast crackers 
with peanut butter. Other suggestions include: 
*drinking the liquid solution with a straw 
placed at the back of the throat, 
thereby bypassing the taste buds, 
*sucking on a frozen Popsicle before and 
after taking the drug to numb the taste 
buds, 
*using a syringe to fill empty capsules 
with the liquid, and swallowini; the 
capsules, 
*eating something very sweet before and 
after to overwhelm the taste buds. 
People having problems with side effects 
should notify a physician. A different treat-
ment regimen may be needed. Switching from 
ritonavir to another protease inhibitor or non-
nucleoside reverse transcriptase inhibitor may 
require dose adjustments of drugs in the new 
regimen, as ritonavir blocks an enzyme that 
these drugs require to be processed in the 
body. If a person chooses to stop taking the 
drug without replacing it, it is important to stop 
all HIV antiviral medications together. 
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This avoids creating a period of weakened 
therapy that would encourage development of 
resistance. Preventive medications for 
opportunistic infections, like Dapsone or 
Septre/Bactrim to prevent PCP should be 
continued, however. 
The liquid formulation of ritonavir contains 
45% alcohol so people in alcohol recovery 
programs need to consider this before starting 
to use the liquid. Furthermore, ritonavir is not 
recommended for people with hepatitis B or 
hepatitis C virus. 
Switching vs. Sticking with Ritonavir 
This question is now being faced by almost 
every one who has used ritonavir. Though 
there isn't one right answer for everyone, a 
few guidelines are possible. Ritonavir, when 
used properly, is among the most potent 
protease inhibitors. It should not be discarded 
casually. An alternative regimen might or 
might not offer the same level of potency. 
*If treatment with ritonavir is marginal or 
beginning to fail, this is the time to 
switch. When switching, it might be wise 
to consider getting a resistance test 
done, if possible, to guide the next choice 
of therapy. 
*If you really like the results you're getting 
with ritonavir, just stick with it and try to 
cope with the taste issue. 
*If treatment is working and you can adhere 
well, try the liquid for a week to see if you 
can live with it. Many people can. Use of 
the liquid will only be temporary. If you 
find it unacceptable, almost any other 
protease inhibitor is a reasonable 
substitute. 
If you decide to switch to something else, 
please consider the following: 
*Review available materials (Project Inform 
and others) about the relative potency, 
durability and side effects of the available 
drugs. 
*Unless you have developed resistance to 
ritonavir, you should be able to switch 
back to it whenever desired. 
*The value of switching to a so-called 
"protease sparing" regimen is unclear for 
people with prior use of protease 
inhibitors. 
*If you have used all the drugs in your 
combination for a year or longer, consider 
changing all of them at once. 
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Poll Shows Cavalier AIDS Attitude 
UPI (11/30/98) 
Board OK's HIV Case Reporting Some States Refuse to Pay for HIV Drug 
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Dallas Morning News Online (11 /21 /98) Unless Maker DuPont Agrees to Discounts 
Wall Street Journal (11 /19/98) 
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A Harris poll by the American 
Foundation for AIDS Research (AmFAR) 
indicates that most Americans are not 
particularly concerned with their risk of 
contracting HIV. According to Mathilde 
Krim, chairperson of AmFAR, "Most 
Americans think they are more likely to 
be shot by a total stranger or go 
completely deaf rather than be infected 
with HIV, thevirusthatcausesAIDS." 
Fear of AIDS ranked last on a list of 11 
different accidents and illnesses in the 
poll. Despite the fact that deaths due to 
AIDS have decreased in the United 
States, AIDS is still a major global 
problem. In the United States, half of all 
new HIV infections occur in people 
under the age of 24 years; however, 
respondents aged 18 to 24 also ranked 
HIV/ AIDS last in the survey. 
Urine Test Finds HIV 
When Blood Test Can't 
Salt Lake Tribune Online (12/03/98) 
A large-scale study of HIV screening 
found that in some cases urine tests 
showed antibodies against HIV-1 in 
some low-risk individuals, while blood 
tests from the same individuals did not. 
According to the Clinical Reference 
Laboratory in Kansas, one of the largest 
testing labs in the country, approxi-
mately one of every 1,000 low-risk 
individuals tested positive for HIV-1 
antibodies in their urine but not in their 
blood. Of 25,000 subjects, 24 were 
found to have the antibodies in their 
urine, but not in their blood samples. 
The lab suggests that people who 
receive HIV tests receive both blood and 
urine assays. Some researchers note 
that the findings support the idea that 
the virus can "compartmentalize", 
reproducing and isolating in tissues 
away from the blood. 
The Texas Board of Health unanimously 
voted to require medical providers to report 
the names of HIV-infected people in the state 
as of January 1. The chairman of the board, Dr. 
Walter Wilkerson, said that the measure will 
improve HIV surveillance, allowing for 
increased tracking of partners and improving 
treatment access. Wilkerson added that the 
names of the infected patients will be kept 
confidential and will only be used for public 
heath services. However, many AIDS activists 
remain opposed to the measure, arguing that 
name-based reporting could keep some 
individuals from being tested. 
Texas currently uses an identifying code for 
HIV reporting in place of the patient's name; 
but Dr. Sharilyn Stanley, head of the health 
department's Bureau of HIV/STD Prevention, 
said that the system was a failure. "We have 
only been getting about 25 percent of the total 
number of cases of HIV reported," she 
explained. Anonymous testing will still be 
available for people who do not want their 
names reported. 
FDA Approves Nevirapine 
for Pediatric HIV Infection 
Reuters (11 /24/98) 
The Food and Drug Administration approved 
nevirapine, a non-nucleoside reverse 
transcriptase inhibitor (NNRTI), for use in HIV-
infected children. Nevirapine is the first NNRTI 
to be approved for children. Clinical trials 
showed the drug to effectively suppress HIV-1 
viral load in children and to be well-tolerated, 
although one study found that 16 percent of 
children on the drug developed a related rash. 
"With HIV, you have to kill all of the virus no 
matter where it lurks in blood and tissue. Even a 
few surviving viruses can sow the seeds of life-
threatening infection throughout the immune sys-
tem all over again" 
- Dr. Anthony Fauci, Director of the National Institute of Allergy 
and Infectious Disease, commenting in USA Today that there is no cure for AIDS. 
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A number of large states, including New 
York and California, have decided not to pay for 
DuPont's HIV drug Sustiva unless the drug 
maker agrees to discuss significant discounts. 
Although the drug, which can be taken just 
once daily, has been widely accepted since its 
launch in September, states are balking at the 
steep annual wholesale price ($3,920) which 
is roughly double the price of two other drugs 
on the market. 
Expensive new drugs are seen raising the 
average monthly costs of state-run AIDS Drug 
Assistance Programs to about $700 million in 
the fiscal year ending March 1, 2000, from 
nearly $52 million in fiscal 1996. Meanwhile, 
Dupont says Sustiva should be sold at a 
premium because it is stronger than other HIV 
drugs and the firm needs to earn the amount it 
spent on development. The company, 
however, offered a 5 percent reduction, in 
addition to the 15 percent reduction for state 
programs required by federal rules, for a two-
week period in October. 
States Asked to Track HIV Cases 
Los Angeles Times (12/10/98) 
With the publication of new guidelines, the 
Centers for Disease Control and Prevention 
will urge states to institute mandatory 
reporting of HIV in order to track the disease. 
While the CDC advocates name-based 
reporting, individual states will be able to 
decide what sort of reporting system they 
wish to use. To ensure confidentiality, HIV 
reporting will have to conform to certain 
requirements created by the CDC no matter 
what type of system is instituted. Many agree 
that HIV reporting is imperative to generate 
accurate statistics concerning the spread of 
the disease; however, some fear that the use 
of name-based HIV reporting will result in a 
breach of confidentiality and could deter 
people from getting tested. 
Some states have opted to use "unique 
identifier codes", which report HIV cases 
without reporting patient names. The use of 
unique identifiers, though, may not be 
advantageous for partner notification and 
could be less practical. In either case, the CDC 
still advocates the continued availability of 
anonymous testing sites. The new guidelines 
will be published in the Federal Register. 
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MEDICAL ASSISTANT FUNDS 
An important reminder to clients: 
There are funds available to TAP clients with financial need 
for the following items: Routine Dental Care, Routine Eye 
Care and Eyeglasses, Vitamin Supplements, Non-
Prescription Skin Care Products, and Non-Medicaid 
Medication Co-pays. 
There is a dollar limit to how much a client can receive in 
any fiscal year. Contact your case manager for assistance. 
FREE LUNCH 
Enjoy a free lunch at The AIDS Project every Thursday at 
noon. Join other clients and TAP staff for a great meal, good 
conversation, and very good company. Drop on by 
Thursdays at noon! 
IMMEDIATE SEATING 
FOR PEOPLE INFECTED 
AND AFFECTED BY HIV/AIDS 
TUESDAYS 
Time: 10:30 a.m. to noon 
Group: HIV Infected/Affected Drop-In Support Group 
A meeting for people living with and affected by the virus. 
Location: Portland, TAP. The Meeting Place, Suite 632. 
J- Contact Randy May at TAP at 774-6877 for more information. 
CX: Time: 1 :30 p.m. to 3:00 p.m. 
O Dates: Started September 22nd, Meets every other Tuesday 
a_ Group: Women with HIV 
a_ A bi-weekly meeting of women living with HIV. 
:::) Sponsored by The AIDS Project (TAP) 
(/) and The AIDS Consultation Service (ACS) 
at Maine Medical Center. 
Location: Portland, ACS, 52 Gilman Street. 
Contact Janine Collins at TAP at 774-6877 
For free tickets to area events as they become available, sign up for 
"Immediate Seating." Call TAP at 774-6877 for more information. 
or Cindy Luce at ACS at 871-2391 for more information. 
Time: 1 :30 p.m. to 3:00 p.m. 
I.V LEAGUE 
Meetings of the I.V. League support group are held on 
Wednesdays at 11 :00 a.m. at the Parkside Community 
Center, 94 Mellen Street, in Portland. 
For more information, call 874-8775. 
THE MEETING PLACE 
This room is used by TAP in Portland for support groups, counseling 
and testing, and some clienVcase manager meetings. Located in 
Suite 632, it provides more privacy for people served by TAP. 
Enter from the High Street side of the building. 
Group: People Living with HIV 
An ongoing drop-in support group for people living with HIV. 
Location: Auburn, TAP. One Auburn Center. 
Contact Diana Carrigan at TAP at 783-4301 for more info. 
THURSDAYS 
Time: 10:00 a.m. to 11 :30 a.m. 
Group: HIV Infected/Affected Drop-in Group 
A TAP-sponsored meeting for people 
living with and affected by HIV/AIDS in southern Maine. 
Location: Sanford, Unitarian Church, located at the corner of 
Main St. (Rte. 109) and Lebanon St. (Rte. 202). 
Contact Getty Payson at TAP at 985-8199 for more info. 
Time: 12 noon 
Group: Open Lunch for TAP Clients/Staff 
An informal luncheon gathering of TAP staff and clients. 
Location: Portland, TAP. Conference Room. 
Contact Randy May at TAP at 774-6877 for more information. 
Time: 5:30 p.m. to 7:00 p.m. 
Group: People Uving with HIV/AIDS 
A drop-in support group for anyone with HIV/AIDS. 
Location: Portland, TAP. The Meeting Place, Suite 632. 
Contact Randy May at TAP at 774-6877 for more information. 
FOR YOUR INFORMATION 
TAP ON-LINE HIV WEBSITES AIDS HOTLINES 
Visit our new website at: 
"www.aidsproject.org" 
To e-mail The AIDS Project, 
send your message along to 
''tap@aidsproject.org" 
Check out these websites: 
www.hivpositive.com 
www.thebody.com 
www.projinf.org 
for info on HIV and AIDS. 
Questions about HIV/AIDS? 
Call toll-free 
National AIDS Hotline: 
1-800-342-2437 
Maine AIDSline: 
1-800-851-2437 
Maine Teen Hotline: 
1-800-851-2437 
(on Wednesdays from 6-9pm) 
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